Aileron Therapeutics company info

What does Aileron Therapeutics do?
Aileron Therapeutics (NASDAQ:ALRN) is a biopharmaceutical company focused on developing and commercializing a novel class of therapeutics called stapled peptides designed to address the challenges of existing cancer treatments. By pioneering a technology that reinforces the body’s ability to fight cancer, Aileron is committed to advancing its lead candidate, ALRN-6924, through clinical trials with the objective of offering new hope to patients battling various types of cancer. The company's projects aim to harness the power of p53, a protein known as the "guardian of the genome," to reactivate the body's natural tumor suppression abilities, offering a potentially transformative approach to cancer care. Through its innovative research and development efforts, Aileron strives to achieve groundbreaking success in the realm of oncology, making significant strides towards its mission of improving patient outcomes.
Aileron Therapeutics company media
Company Snapshot

Is Aileron Therapeutics a public or private company?

key
Ownership
Public

How many people does Aileron Therapeutics employ?

people
Employees
15

What sector is Aileron Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Aileron Therapeutics?

location pin
Head Office
Cambridge, United States

What year was Aileron Therapeutics founded?

founded flag
Year Founded
2001
What does Aileron Therapeutics specialise in?
/Peptide Therapeutics /Cancer Treatments /Stapled Peptides /Drug Discovery /Pharmaceutical Research /Clinical Development

What are the products and/or services of Aileron Therapeutics?

Overview of Aileron Therapeutics offerings
ALRN-6924, a dual inhibitor of p53-MDM2 and p53-MDMX, positioned for the treatment of cancers by restoring p53 tumor suppression.
Development of novel cell-permeating peptides aimed at treating various types of cancers including solid tumors.
Collaboration with research institutions for the advancement of peptide-based therapeutics for oncology.
Preclinical research projects focused on enhancing the delivery and efficacy of peptide-based drugs.
Initiatives to expand the application of their proprietary stapled peptide technology in other therapeutic areas beyond oncology.
Engagement in strategic partnerships for the development and commercialization of their pipeline products.

Who is in the executive team of Aileron Therapeutics?

Aileron Therapeutics leadership team
  • Dr. James Brian Windsor Ph.D.
    Dr. James Brian Windsor Ph.D.
    CEO & Director
  • Mr. Charles T. Garner
    Mr. Charles T. Garner
    Principal Financial & Acconting Officer